Press Releases

January 18, 2022

Mabwell is Officially Listed on the Shanghai Stock Exchange STAR Market

Read more

October 19, 2021

China’s First Anti-Nectin-4 ADC Drug Receives IND Approval

Read more

May 8, 2021

First China-made Anti-ST2 Antibody Developed by Mabwell Approved for Clinical Study

Read more

February 5, 2021

Mabwell participated in the Shanghai Biopharmaceutical Industry Innovation Alliance as the Secretary-General

Read more

May 9, 2020

Mabwell Closes Series A Financing of 1.97 Billion Yuan to Speed Up New Variety R&D and Industrialization

Read more

Attention Investors

We are on the lookout for investors interested in working with us to advance our own pipeline in the United States. We also seek in-licensing opportunities for novel therapeutics to initiate clinical testing and registration in China.